Lilly’s weight loss drug (anti-diabetes) Tirzepatide in the United States sold about RMB 250 billion in 2025, becoming the “top miracle drug” in history. Looking at Lilly’s Q1 financial report this year, its total revenue grew 56% year over year to $19.8 billion, and the main credit still comes from the sales growth of Tirzepatide…

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin